2Marr KA, Carter RA, Beoekh M, et al. Invasive aspergillosis in allogeneie stem cell transplant recipients : changes in epidemiology and risk faetors[J]. Blood,2002,100(24) :4358-4366.
4Liebowitz LD, Ashbee HR, Evans EG, et al. A two year global evalution of susceptibility of Candida species to flueonazole by disk diffusion[J]. Diagn Mierobiol Infect Dis, 2001,40 (1) : 27- 33.
3Jarvis WR . Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis, 1995,20:1526-1530.
4Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis, 1999,29:1164-1170.
5Verduyn Lunel FM, Meis JF, Voss A, et al. Nosocomial fungal infections:candidemia. Diagn Microbiol Infect Dis, 1999,34:213-220.
6Edmond MB, Wallace SE, McClish DK,et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis, 1999,29: 239-244.
7Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990.National Nosocomail Infections Surveillance System . J Infect Dis, 1993, 167:1247-1251.
8Haddad NE, Powderly WG. The changing face of mycoses in patients with HIV/AIDS. AIDS Read, 2001,11: 375-378.
9Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis, 1995,21:994-996.
10Pfalller MA, Messer SA, Hollis RJ, et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis, 1999,33:217-222.
